- Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke2026-05-26
The Novo Nordisk study POSEIDON – including 18,904 patients across 18 countries - showed that cardiovascular (CV) inflammation remains highly prevalent among people with cardiovascular disease (CVD), despite current standard of care treatment 1,2 In fact, two in five people with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD), or heart failure, have CV inflammation 1,2 This matters because CV inflammation is an independent risk factor for CV events, such as heart attack and stroke, in people living with CVD, and it shows a significant gap in CV care globally 3 Bagsværd, Denmark, 26 May 2026 – Novo Nordisk today presented new results from the landmark POSEIDON real-world evidence study at the 94 th European Atherosclerosis Society (EAS) Congress in Athens, Greece. The study showed that CV inflammation remains highly prevalent among people with CVD despite current standard-of-care treatment. The study found that 2 in 5 people with ASCVD and CKD had CV infl
- Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide2026-05-19
Trial liver safety data from the ‘ESSENCE’ trial confirm semaglutide's favourable hepatic profile in patients with Metabolic Dysfunction-associated Steatohepatitis (MASH), addressing a critical concern for clinicians treating a disease with historically limited and poorly tolerated options. New subgroup analyses — including the first dedicated Japanese MASH population data and women in menopause — show semaglutide's benefits extend broadly, underscoring its potential to serve the full, diverse spectrum of patients living with this silent epidemic, with nine out of 10 cases undiagnosed globally. Real-world evidence presented at EASL Congress 2026 reveals the devastating and largely hidden challenge of MASH: significant impairment in quality of life, soaring healthcare costs, and a patient population that remains critically underdiagnosed and undertreated. Bagsværd, Denmark, 19 May 2026 – At the European Association for the Study of the Liver (EASL) Annual Congress 2026 on 27-30 May in B
- Novo Nordisk A/S - share repurchase programme2026-05-18
Bagsværd, Denmark,18 May 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027. Since the announcement of the programme, the following transactions have been made: Number of B shares Average purchase price Transaction value, DKK 6 May 2026 199,849 300.66 60,086,659 7 May 2026 200,000 294.37 58,873,625 8 May 2026 210,000 290.45 60,993,987 11 May 2026 210,000 300.49 63,103,075 12 May 2026 210,000 300.81 63,169,735 13 May 2026 210,000 3
- Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO20262026-05-13
Almost a third of adults taking Wegovy ® pill (oral semaglutide 25 mg) were early responders to treatment, achieving an average of 13.2% weight loss after four months and 21.6% weight loss at the end of the OASIS 4 clinical trial 1 . Nearly eight in 10 people with poor physical function who took the Wegovy ® pill almost doubled their ability to move, including bending over, standing comfortably and staying active, compared to placebo 2 . The ORION indirect treatment comparison and the OPTIC patient preference studies, now published (abstract) at the European Congress on Obesity, demonstrated that Wegovy ® pill provides greater weight loss than orforglipron and has lower odds of stopping medication due to side effects 3-5 . Bagsvær d, Denmark, 13 May 2026 – Novo Nordisk today presented new sub-analyses from the phase 3 OASIS 4 clinical trial at the European Congress on Obesity 2026 (ECO2026) in Istanbul, Türkiye, showing how well Wegovy ® pill (oral semaglutide 25 mg) works in adults li
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons2026-05-12
Bagsværd, Denmark, 12 May 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a) Name of the Board member/Executive/Associated Person Caroline Munk Esbjerg 2 Reason for the notification a) Position/status Closely associated person to Karsten Munk Knudsen, Executive Vice President, Chief Financial Officer (CFO) b) Initial notification/Amendment Initial notification 3 Details of the issuer a) Name Novo Nordisk A/S b) LEI 549300DAQ1CVT6CXN342 4 Details of the transaction(s) a) Description of the financial instrument, type of instrument, Shares Identification code Novo Nordisk B DK0062498333 b)
